These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 30646864)

  • 21. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
    Bouchet C; Ferrero-Poüs M; Hacène K; Becette V; Spyratos F
    Int J Biol Markers; 2003; 18(3):207-17. PubMed ID: 14535592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
    Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
    Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
    PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A; Ulu A; Cam R; Akar N
    J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.
    Yagmurdur MC; Atac FB; Tutar NU; Verdi H; Isiklar I; Ozdemir BH; Ozbek N; Karakayali H; Haberal M
    Int Surg; 2008; 93(3):163-8. PubMed ID: 18828272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
    Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
    BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
    Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Foekens JA; Beex LV; Sweep CG
    Cancer Res; 2004 Jan; 64(2):659-64. PubMed ID: 14744782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
    Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
    Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
    Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H
    Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA
    Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.